Canine Separation Anxiety Treatment Market

Canine Separation Anxiety Treatment Market By Drug Molecule (Amitriptyline, Buspirone, Clomipramine), By Anxiety Type (Aggressive anxiety, Non-aggressive anxiety), By Distribution Channel - Global Market Insights 2021 to 2031

Analysis of Canine Separation Anxiety Treatment market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Canine Separation Anxiety Treatment Market Outlook

Canine separation anxiety treatment market analysis shows that global market value enjoyed year-on-year (YoY) growth of 5.4% in 2021, with the market valued at US$ 22.45 Mn.

Value of aggressive anxiety treatment is expected to increase to US$ 26.13 Mn, while that of non-anxiety treatment to US$ 13.85 Mn in 2031.

Key Points Covered in Canine Separation Anxiety Treatment Industry Survey:

  • Market Estimates and Forecasts (2016-2031)
  • Key Drivers and Restraints Shaping Market Growth
  • Segment-wise, Country-wise and Region-wise Analysis
  • Competition Mapping and Benchmarking
  • Market Share Analysis
  • COVID-19 Impact on Canine Separation Anxiety Treatment and How to Navigate
  • Recommendation on Key Winning Strategies

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Industry Analysis of Canine Separation Anxiety Treatment from 2016 to 2020 Compared to Demand Outlook for 2021 to 2031

According to Fact.MR - a market research and competitive intelligence provider, in 2020, the global canine separation anxiety treatment market was valued at US$ 21.4 Mn in 2020, and has been expanding at a CAGR of 4.3% over the past years. High prevalence of canine anxiety rising high adoption of canines are primary factors contributing to growth of the market.

On the other hand, the current COVID-19 pandemic has led to a moderate negative impact on the sales of canine separation treatment drugs. As more pet owners have been working from home during this time frame (2020-2021), separation anxiety issues have lessened to a great extent.

However, with the relaxation of lockdown curbs and commencement of vaccination drives, most pet parents will return to work. This increases the chances of developing separation anxiety disorders among canines, and thus creates demand for drugs to calm them down.

Overall, the market of medication for separation anxiety is expected to expand at around 6% CAGR through 2031.

Are Limited Number of Approved Drugs Impacting Growth of the Canine Separation Anxiety Treatment Industry?

Considering the global prevalence of canine separation anxiety, lesser number of drugs are approved. The U.S. FDA has approved only two prescription drugs that are used specifically to treat canine separation anxiety. Clomipramine (Elanco Animal Health) and fluoxetine hydrochloride (Reconcile, Pegasus Laboratories, Inc.) are approved for treating the behavioural disorder.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Will High Cost of Veterinary Care Hamper Demand for Canine Separation Anxiety Treatment?

Despite the growing trend of pet care insurance, the number of pets covered for treatment is very low. Consequently, pet parents have to bear with majority of the cost of treatment, including routine visits, surgeries, and other health conditions.

One of the primary causes for increase in veterinarian expenses is that medicine technology has progressed. Moreover, every pet, be it a dog or cat, has their own unique personality and independent needs. Also, if a pet owner has dogs two of different breeds, it requires different medical attention. This is yet another factor responsible for rise in veterinary costs.

Also, some medicines are required to be taken by the pet for an extended amount of time or even throughout their life, and this quickly adds up to the overall medication cost.

canine separation anxiety treatment market end User by FactMR

What are the Key Opportunities for Stakeholders in Canine Separation Anxiety Treatment?

Overall cost of treating canine separation anxiety is significantly higher with branded drugs, and is anticipated to remain higher, especially when compared with generic or other extra-label/off-label drugs. These higher costs have driven demand of lower cost treatment alternatives. For example, demand for diazepam for canines has seen a gradual decrease over the years.

Also, some of the approved drugs such as Clomipramine have lost their patent, which had led to the development of generic versions. Thus, demand for lower cost alternatives are expected to create lucrative opportunities for players operating in the canine separation anxiety treatment space. Sales of amitriptyline for dogs have been witnessing a decrease over the years. Similarly, demand for amitriptyline for dogs has also been affected.

Don't Need a Global Report?

save 40%! on Country & Region specific reports

Country-wise Analysis

What Makes the U.S. a Large Market for Canine Separation Anxiety Treatment?

The canine separation anxiety treatment industry survey for the U.S. estimates that the market topped US$ 6.4 Mn in 2020. Growth is attributed to high number of dogs suffering from canine separation anxiety in the country.

Canines suffering from separation anxiety are very attached to their owners and get extremely disturbed when left alone. In response to this, they show aggressive behavior.

Approximately 13 million dogs in the U.S. suffer from canine separation anxiety, which has a huge impact on their quality of life and long-term health. Thus, high number of dogs suffering from canine separation anxiety will drive he demand for medications to calm their aggressive behavior, which is anticipated to drive market in the country.

How is Canine Separation Anxiety Treatment Demand Outlook Shaping in China?

The market in China is anticipated to reach US$ 6.8 Mn by 2031, and is expected to expand at a CAGR of 7% over the forecast period. High adoption of canines as compared to other pets in China is one of the primary factors creating a positive impact on market growth. According to a Chinese pet industry whitepaper, in 2019, overall, 55 million canines were adopted as compared to 44.1 million cats.

Greater adoption of canine population is expected to drive demand for canine healthcare and medication services, including the treatment for separation anxiety.

Category-wise Insights

Why is Clomipramine to Most Preferred Drug Used to Treat Canine Separation Anxiety?

Clomipramine is expected to be the most preferred type of drug used to treat canine separation anxiety. Also, Clomipramine is the most effective in reducing separation-related behavior by calming anxiety issues.

Clomipramine, when administered at a dosage of 1mg/kg at a 12-hour interval, increases passive behavior and reduces pacing scratching and whining of dogs in absence of its owner. Also, when the dosage is increased to 2mg/kg every 12 hours, it produces additional improvements and promotes more passive behavior when dogs are left alone.

Owing to these benefits, demand for Clomipramine is growing among veterinarians to treat canine separation anxiety issues, thus capturing the largest share in the market by drug molecule.

How Big is the Opportunity for Online Veterinary Pharmacies for Canine Separation Anxiety Treatment?

The distribution structure of veterinary drugs is changing as the Internet becomes more widely accessible around the world. The number of online veterinary pharmacies is growing, as pet owners increasingly use the Internet to research disease signs and place orders for over-the-counter (OTC) drugs as well as prescription drugs.

Also, certain compounding pharmacies provide doorstep deliveries of vet medicines after receiving online orders. This trend is most common in the U.S., Europe, and Pacific countries, owing to the availability of online catalogues for prescription drugs.

Moreover, to capitalize on the growth opportunities, venture capital firms are investing in e-Commerce to provide dispensing services to pet owners.

In this regard, Vets First Choice, in July 2017, raised US$ 223 million to introduce its new innovative services and expand its offerings in the European and Asian markets. The Vets First Choice platform enables practitioners to track medication and service compliance as well as connect clients proactively to solve unmet pet care needs.

Additionally, Vets First Choice uses an e-Commerce platform to help veterinarians compete with larger online competitors by facilitating medicine dispensing to pet owners.

PetCareRx (US), Wedgewood Pharmacy (US), Pet Care Pharmacy (Australia), 365Vet (UK), and Petdrugsonline (UK) are some of online pharmacies offering medications for canine separation anxiety.

Thus, online availability of canine medicines provides an array of opportunities for market growth.

canine separation anxiety treatment market competition by FactMR

Insights into Canine Separation Anxiety Treatment Market Competition Analysis

Market players involved in canine separation anxiety treatment are engaged in expanding their regional presence through acquisitions, collaborations, expansions, product launches, and strengthening their existing distribution network.

  • In August 2019, Zoetis acquired Platinum Performance, a nutrition-focused animal health business, which offers its nutritional products formulas for dogs, cats, and horses.
  • In October 2019, Zoetis acquired Phoenix Lab, a leading veterinary reference laboratory, to enhance its offerings in veterinary diagnostic space.
  • In November 2016, Pegasus Laboratory (PRN Pharmacal) acquired Veterinary Products Laboratories (VPL) animal health, which focused on providing veterinary products for companion animals.

Report Scope



Forecast Period


Historical Data Available for


Market Analysis

US$ Mn for Value

Key Regions Covered

  • North America
  • Latin America
  • Europe
  • MEA
  • East Asia
  • South Asia
  • Oceania

Key Countries Covered

  • US
  • Canada
  • Brazil
  • Mexico
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Russia
  • China
  • Japan
  • South Korea
  • India
  • Thailand
  • Indonesia
  • Malaysia
  • Australia
  • New Zealand
  • South Africa
  • GCC Countries
  • Turkey
  • GCC Countries

Key Market Segments Covered

  • Drug Molecule
  • Anxiety Type
  • Distribution Channel
  • Region

Key Companies Profiled

  • Elanco Animal Health
  • Pegasus Laboratories Inc. (PRN Pharmacal)
  • Zoetis Inc.
  • Pfizer Inc.
  • Virbac SA
  • Mizner Bioscience LLC
  • Dechra Pharmaceuticals PLC
  • Teva Pharmaceutical Industries Ltd.
  • Apotex Inc.


Available upon Request

Key Market Segments Covered in Canine Separation Anxiety Treatment Industry Research

  • By Drug Molecule

    • Alprazolam (XanaX) Canine Separation Anxiety Treatment
    • Amitriptyline Canine Separation Anxiety Treatment
    • Buspirone Canine Separation Anxiety Treatment
    • Clomipramine Canine Separation Anxiety Treatment
    • Dexmedetomidine Canine Separation Anxiety Treatment
    • Diazepam (Valium) Canine Separation Anxiety Treatment
    • Fluoxetine Hydrochloride Canine Separation Anxiety Treatment
    • Others
  • By Anxiety Type

    • Aggressive Canine Separation Anxiety Treatment
    • Non-Aggressive Canine Separation Anxiety Treatment
  • By Distribution Channel

    • Canine Separation Anxiety Treatment through Veterinary Hospitals
    • Canine Separation Anxiety Treatment through Veterinary Clinics
    • Canine Separation Anxiety Treatment through Pharmacies & Drug Stores
    • Canine Separation Anxiety Treatment through Online Pharmacies

- FAQs -

The global canine separation anxiety treatment market is worth at US$ 22.45, and is set to expand 2X over the next ten years.

The market is expected to reach US$ 39.9 Mn by the end of 2031, with sales revenue expected to register a CAGR of close to 6% over the forecast period.

From 2016-2020, the canine separation anxiety treatment industry expanded at the rate of 4.3%, owing to high prevalence of canine separation anxiety disorders across regions.

Growing preference for pet Insurance, demand for generic drugs, and market consolidation are some of the key trends in this market space.

The U.S., China, Brazil, India, and Germany are expected to drive most demand for canine separation anxiety treatment.

North America is one of the key markets for canine separation anxiety treatment. According to Fact.MR, the U.S. is expected to account for over 90% of the North American market through 2031.


Demand of canine separation anxiety treatment is expected to register a growth rate of 5% in Europe over the next ten years.

The U.S., Canada, Germany, U.K., France, and Australia are key players in this market.

The U.S. is one of the key providers of canine separation anxiety treatment in the world.

Though Japan’s veterinary pharmaceutical market is growing slower than other developed nations, demand for canine separation anxiety treatment will exhibit growth at 7.3% CAGR. South Korea holds revenue share of 7%

Canine Separation Anxiety Treatment Market

Schedule a Call

We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic.

By clicking "Accept All", you consent to our use of cookies. Privacy Policy